Versant Ventures Launches Pep2Tango Therapeutics with Revolutionary Tetra-Receptor Agonist Approach for Obesity Treatment

Company Launch:
Versant Ventures has unveiled Pep2Tango Therapeutics Inc., a startup focused on developing next-generation weight loss therapies[1][2].

Tetra-Receptor Agonist Approach:
Pep2Tango's lead drug candidates are unimolecular multi-receptor peptide agonists targeting GLP-1, GIP, amylin, and calcitonin receptors, offering a unique combination of targets in one molecule[1][2].

Preclinical Results:
Preclinical studies have demonstrated superior weight loss versus tirzepatide, primarily through selective fat mass loss with preservation of muscle mass, improved blood lipid profiles, better glycemic control, and beneficial effects on the liver[1][2].

Development Plans:
Pep2Tango is focused on CMC development activities to scale up drug candidate manufacturing and on running IND-enabling studies for a rapid transition to first-in-human clinical studies, with an IND submission expected in 2025[1][2].

Backing:
Pep2Tango Therapeutics is backed by Versant Ventures, a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies[1][2].